Local treatment with electrochemotherapy of superficial angiosarcomas

Efficacy and safety results from a multi-institutional retrospective study

Michele Guida, Luca Giovanni Campana, Pietro Curatolo, Sabino Strippoli, Antonio Bonadies, G. Grilz, Carlo Cabula, Roberta Rotunno, Stefania Bucher, Nicola Solari, A. Santoriello, Sara Valpione, Carlo Riccardo Rossi

Research output: Contribution to journalArticle

Abstract

Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. © 2016 Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)246-253
Number of pages8
JournalJournal of Surgical Oncology
Volume114
Issue number2
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Electrochemotherapy
Hemangiosarcoma
Retrospective Studies
Safety
Disease-Free Survival
Therapeutics
Vascular Neoplasms
Neoplasms
Skin
Bleomycin
Scalp
Breast
Hemorrhage
Recurrence
Pain

Keywords

  • bleomycin
  • drug delivery systems
  • electrochemotherapy
  • hemangiosarcoma
  • local
  • neoplasm recurrence
  • vascular neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Local treatment with electrochemotherapy of superficial angiosarcomas : Efficacy and safety results from a multi-institutional retrospective study. / Guida, Michele; Campana, Luca Giovanni; Curatolo, Pietro; Strippoli, Sabino; Bonadies, Antonio; Grilz, G.; Cabula, Carlo; Rotunno, Roberta; Bucher, Stefania; Solari, Nicola; Santoriello, A.; Valpione, Sara; Rossi, Carlo Riccardo.

In: Journal of Surgical Oncology, Vol. 114, No. 2, 01.08.2016, p. 246-253.

Research output: Contribution to journalArticle

Guida, M, Campana, LG, Curatolo, P, Strippoli, S, Bonadies, A, Grilz, G, Cabula, C, Rotunno, R, Bucher, S, Solari, N, Santoriello, A, Valpione, S & Rossi, CR 2016, 'Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study', Journal of Surgical Oncology, vol. 114, no. 2, pp. 246-253. https://doi.org/10.1002/jso.24287
Guida, Michele ; Campana, Luca Giovanni ; Curatolo, Pietro ; Strippoli, Sabino ; Bonadies, Antonio ; Grilz, G. ; Cabula, Carlo ; Rotunno, Roberta ; Bucher, Stefania ; Solari, Nicola ; Santoriello, A. ; Valpione, Sara ; Rossi, Carlo Riccardo. / Local treatment with electrochemotherapy of superficial angiosarcomas : Efficacy and safety results from a multi-institutional retrospective study. In: Journal of Surgical Oncology. 2016 ; Vol. 114, No. 2. pp. 246-253.
@article{1fafba26985140f382e21345c00b7f07,
title = "Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study",
abstract = "Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63{\%}) patients, complete in 8 (42{\%}). One-year LPFS within treatment field was 68{\%}. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. {\circledC} 2016 Wiley Periodicals, Inc.",
keywords = "bleomycin, drug delivery systems, electrochemotherapy, hemangiosarcoma, local, neoplasm recurrence, vascular neoplasms",
author = "Michele Guida and Campana, {Luca Giovanni} and Pietro Curatolo and Sabino Strippoli and Antonio Bonadies and G. Grilz and Carlo Cabula and Roberta Rotunno and Stefania Bucher and Nicola Solari and A. Santoriello and Sara Valpione and Rossi, {Carlo Riccardo}",
year = "2016",
month = "8",
day = "1",
doi = "10.1002/jso.24287",
language = "English",
volume = "114",
pages = "246--253",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Local treatment with electrochemotherapy of superficial angiosarcomas

T2 - Efficacy and safety results from a multi-institutional retrospective study

AU - Guida, Michele

AU - Campana, Luca Giovanni

AU - Curatolo, Pietro

AU - Strippoli, Sabino

AU - Bonadies, Antonio

AU - Grilz, G.

AU - Cabula, Carlo

AU - Rotunno, Roberta

AU - Bucher, Stefania

AU - Solari, Nicola

AU - Santoriello, A.

AU - Valpione, Sara

AU - Rossi, Carlo Riccardo

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. © 2016 Wiley Periodicals, Inc.

AB - Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated. Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST (version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated. Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n = 5), breast (n = 8), other skin sites (n = 3), and soft tissue (n = 3). Target lesions (n = 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients). Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas. J. Surg. Oncol. 2016;114:246–253. © 2016 Wiley Periodicals, Inc.

KW - bleomycin

KW - drug delivery systems

KW - electrochemotherapy

KW - hemangiosarcoma

KW - local

KW - neoplasm recurrence

KW - vascular neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84978517828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978517828&partnerID=8YFLogxK

U2 - 10.1002/jso.24287

DO - 10.1002/jso.24287

M3 - Article

VL - 114

SP - 246

EP - 253

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 2

ER -